

THE WHARTON SCHOOL
University of Pennsylvania

The Economics and Financing of Health Care Delivery
HCMG 202-401/ECON 39
Fall 2009

Jonathan Kolstad
108 Colonial Penn Center
e-mail: jkolstad@wharton.upenn.edu

Teaching Assistant

Andrea Puig
Colonial Penn Center Suite 401
e-mail: apuig@wharton.upenn.edu

Lectures: Tues. & Thurs. 12-1:20
Colonial Penn Center Auditorium
Office Hours: Wed. 1:30-2:30

Office Hours: Thurs. 3-4

Description

The purpose of this course is to consider the economic facts and economic analysis of the medical care sector. In the United States this is a huge and growing industry, accounting for more than \$2 trillion in spending, or roughly 16% of GDP, and a sizeable portion of US employment and research and development.

This course deals, primarily, with research in economics on health care. We will deal with production of health itself and the role of health in consumption of medical resources viewed through the lens of economics models. However, the main focus of the course will follow the main focus of health economics as a field: how medical *care* is produced and financed, in both private and public sectors. Emphasis will be on the US, with a brief treatment of health economics research in other countries and comparisons of health systems in other developed and less developed countries.

The material for the course will consist both of the description and discussion of problems in medical services financing and delivery and analysis of how medical markets work. Fundamentally we will use economics to evaluate why the health care market is different from conventional markets and what, if anything, economic analysis can tell us about these differences. This will include studying such matters as why health insurance exists, whether hospital competition leads to efficient allocation of resources and production, the role of the physician in patient choice and the role for government and market interventions in correcting potential inefficiencies.

This is an economics course. The approach taken and the literature reviewed will be primarily by and for economists. This means that charts, graphs, and algebra will be common. While these tools will be used to analyze interesting political and policy questions, you should not take this course if you already think economics is confusing, maddening, or irrelevant.

The course will also shed light on some more general questions in economics, especially in economic theory, industrial organization and public finance. Many of the important issues in general economics- decisions and markets with uncertainty, principal-agent theory, moral hazard, the behavior of non-profit firms, and the role of fringe benefits in the labor market -have concrete, real world examples in the medical care and health insurance industries. Observation of actual behavior

in this industry can furnish real world tests and policy-relevant challenges for some of the more important recent developments in economic theory.

Readings

The text is Folland, Goodman, and Stano, *The Economics of Health and Health Care* (6th ed.). This is a clear, not-too-complicated exposition. The course website (on WebCafé) will contain additional readings – some on health policy, and some chapters from some recent books which help to update the text. We will also read a substantial portion of David Cutler's book *Pricing the Priceless* (Oxford University Press, 2004). All readings are required.

Notes/slides will also be posted on the WebCafé page for this class, usually within a day of the class session. Non-Wharton students will need a Wharton ID to access the web page. **Wharton IDs can be obtained by going to Wharton Computer Consulting in Room F35, Jon M. Huntsman Hall, or apply online at <http://apps.wharton.upenn.edu/accounts/class/index.cfm>.**

Comments and questions in class are strongly encouraged. Things that seem confusing or controversial are usually that way for many students; everyone will benefit if you ask questions. And because the class will deal with policy, there is a lot of room for honest and good spirited disagreement. No one knows the complete answer, or even the right answer, to many of these questions.

Exams

Both exams will both be essay / short answer tests. The purpose of the exams is to evaluate your understanding of the economic theory, empirical evidence and policy application of the topics covered in the course. The first exam will cover material to that point. The second exam will focus primarily on the second half of the course but may draw on concepts from earlier lectures and readings.

Memos

Three memo opportunities will be offered throughout the semester and you should complete two of them. Memos should not exceed two pages (minimum 1.5 line spacing, font 11). Each memo will be a response to an editorial, short policy paper or letter. Each of the memos will relate to one of the primary topics covered in the course. These will be assigned after covering the topic. Specific question will be associated with each memo, but generally you should critically evaluate the topic using the tools of economics. The key to a successful memo is to apply economics to reach a more subtle conclusion than you would otherwise and to articulate that clearly and succinctly.

Participation

I reserve the right to circulate an attendance list during some classes if numbers dwindle (yes this creates a free rider problem). Grades will take into account whether you actively participate in the course.

Grading

CLASS PARTICIPATION	10 %	Attendance and involvement
POLICY MEMOS	20 %	Two (of three) during the semester
EXAM 1	35 %	October 22 nd
EXAM 2	35 %	December 12 th

Introduction

9/10: Lecture 1

Course Overview

- FGS, Chapters 1; Skim Chapters 2, 3, 18 (383-391)

Cost, Quality and Access

9/15: Lecture 2

Health Care Spending: Why so much? Is it too much?

- Catlin et al., “Trends: National Health Spending In 2007: Slower Drug Spending Contributes to Lowest Rate of Overall Growth Since 1998,” *Health Affairs* 28, no.1 (Jan./Feb. 2009):246-261.
- D. Cutler, Your Money or Your Life, Chapter 2: “Pricing the Priceless.”
- Cutler, D. and M. McClellan. “Is Technological Change Worth It?” *Health Affairs* Sept/Oct. 2001.

Health Production and Demand: Theory Models and Empirical Results

9/17: Lecture 3

The Health Production Function: What Does Medical Care Do? Is it worth it?

- FGS, Chapters 5 and 6.
- Cutler, Your Money or Your Life, Chapters 3-5: “Pricing the Priceless.”

9/22: Lecture 4

The Demand for Health and Medical Care: Theory and Empirics

- FSG Chapter 7

9/24: Lecture 5

The Demand for Medical Care: Effects of Price (and other factors) on Quantity

- FGS, Chapter 9

Health Insurance

9/29: Lecture 6

Demand for Health Insurance and Moral Hazard

- FGS, Chapters 8
- M. Gladwell, “The Moral Hazard Myth.” *The New Yorker*, August 29, 2005.
- M. Pauly. “The Truth about Moral Hazard and Adverse Selection.” Policy Brief No. 36. Center for Policy Research, Maxwell School of Syracuse University, 2007

10/1: Lecture 7

Private Health Insurance: Employer-Sponsored Coverage

- FGS, Chapter 10 and 11
- Pauly, “The Economics of Employer-Paid Benefits,” Chapter 3 in Health Benefits at Work (1997), pp. 37-50.

10/6: Lecture 8

Government Programs: Medicare, Medicaid and SCHIP

- FGS, Chapter 21
- Cutler and Gruber, “Medicaid and Private Insurance: Evidence and Implications.” *Health Affairs* 16(1): 194-200. (Jan/Feb 1997)

10/8: Lecture 9

Private Health Insurance: Individual Coverage and Market Reforms

- G. Claxton. “How Private Insurance Works: A Primer.” Kaiser Family Foundation, April 2002.
- L. Nichols and M. Pauly, “The Non-Group Health Insurance Market: Short on Facts, Long on Policy Disputes and Opinions,” *Health Affairs* Web Exclusive, October 23, 2002.
- D. Chollet, “Expanding Individual Health Insurance Coverage: Are High Risk Pools the Answer?” *Health Affairs* Web Exclusive, October 23, 2002.

10/13: Lecture 10

Managed Care

- FGS, Chapter 12.

- Miller and Luft. “HMO Plan Performance Update” *Health Affairs*, 21(4), July/Aug 2002, p.63-86.
- Newhouse, J. “Consumer Directed Health Plans and the RAND Health Insurance Experiment” *Health Affairs* 23(6) Nov/Dec 2004, p.107-13.

10/15: Lecture 11 The Uninsured

- Gruber, J. “Covering the Uninsured in the United States.” *Journal of Economic Literature*. 46(3): 571-606.

10/20: Lecture 12 Review Session
 10/22 **EXAM 1**

Economics of Health Care Supply

10/27: Lecture 13 Non-Profit Status of Hospitals

- FGS, Chapter 13
- J. Horwitz “Making Profits And Providing Care: Comparing Nonprofit, For-Profit, And Government Hospitals” *Health Affairs*, 24, no. 3 (2005): 790-801

10/29: Lecture 14 Hospital Competition

- FGS, Chapters 14 and 20

11/3: Lecture 15 Physician Agency

- FGS, Chapters 15

International Health Systems

11/5: Lecture 16 Health Systems in Developing Countries

- FGS, Chapter 24
- Pauly, M. et al., “Private Health Insurance in Developing Countries,” *Health Affairs* 25(2) (March/April 2006): 369-379.
- McPake, B, Mills, A. What can we learn from international comparisons of health systems and health system reform? *Bulletin of the World Health Organization*. 78(6), June 2000.
- Wagstaff, A. “Health systems in East Asia: What Can Developing Countries Learn from Japan and the Asian Tigers?” *Health Economics* 16(5): Pages 441 – 456.
- Knaul, FM, Frenk, J. “Health Insurance In Mexico: Achieving Universal Coverage Through Structural Reform.” 2005. 24(6):1467-1476.

11/10: Lecture 17 Health Systems in Developed Countries

- FGS, Chapter 22
- Anderson, GF, Frogner, BK, Reinhardt, Health Spending In OECD Countries In 2004: An Update. *Health Affairs*, 26(5), (2007): 1481-1489
- Van der Zee, J., Kroneman, MW. “Bismarck or Beveridge: A Beauty Contest Between Dinosaurs.” *BMC Health Services Research*, 2007.
- Tapay, N, Colombo, F. Chapter 6: Private Health Insurance in OECD Countries: The Benefits and Costs for Individuals and Health Systems in Towards High-Performin Health Systems Policy Studies OECD 2004, pp. 265- 318.

Selected Topics in Health Economics

11/12: Lecture 18 Health Labor Supply

- FGS, Chapters 16
- H. Berliner and E. Ginzberg. “Why this Hospital Nursing Shortage is Different.” *JAMA* 288(21):2742-2744 (Dec. 4, 2002).

	<ul style="list-style-type: none"> • D. Blumenthal. "New Steam from an Old Cauldron: The Physician-Supply Debate." <i>NEJM</i> 350(17):1780-1787 (April 22, 2004).
11/17: Lecture 19	<p><u>Pharmaceuticals</u> (Guest Lecture by Dr. Patricia Danzon)</p> <ul style="list-style-type: none"> • FGS, Chapter 17 • Scherer, F. "The Pharmaceutical Industry: Prices and Progress", <i>NEJM</i>, 351(9), August 26, 2004, p.927-32. • Berndt, E. "Pharmaceuticals in US Healthcare: Determinants of Quantity and Price," <i>Journal of Economic Perspectives</i>, 16(4), Fall 2002, 45-66.
11/19: Lecture 20	<p><u>Pharmaceuticals contd.</u> (Guest Lecture by Dr. Patricia Danzon)</p> <ul style="list-style-type: none"> • Same as above
11/24: Lecture 21	<p>Health Care Disparities (Guest Lecture by Dr. Rachel Warner)</p> <ul style="list-style-type: none"> • Readings TBA later in the semester
11/26:	<p>Thanksgiving</p>
12/1: Lecture 22	<p><u>Information and Quality in Health Care</u></p> <ul style="list-style-type: none"> • J. Hibbard, J. Stockard and M. Tussler. "Hospital Performance Reports: Impact On Quality, Market Share, And Reputation." <i>Health Affairs</i>, 24, no. 4 (2005): 1150-1160 • J. Kolstad and M. Chernew. "Consumer Decision Making in the Market for Health Insurance and Health Care Services." <i>Medical Care Research and Review</i>, 2008. • D. Cutler, R. Huckman and M. Landrum. "The Role of Information in Medical Markets: An Analysis of Publicly Reported Outcomes in Cardiac Surgery." <i>American Economic Review</i>, 94(2).
12/3: Lecture 23	<p><u>Policy Proposals</u></p> <ul style="list-style-type: none"> • Readings TBA later in semester
12/8: Lecture 24	<p><u>Review and Wrap Up</u></p>
12/10	<p>EXAM 2</p>